MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
Key Highlights
- ➤Q3 revenue $10.2 million, up 49% year over year
- ➤2026 revenue guidance raised to at least $34.5 million
- ➤MaxCyte proposes Akron Bio acquisition, nearly doubling revenue
- ➤Q3 net loss narrowed to $4.8 million from $12.4 million
- ➤Akron deal includes $105.0 million cash payment and $22.0 million debt draw
Expert Statements
Maher Masoud, President and CEO of MaxCyte
“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”
Maher Masoud, President and CEO of MaxCyte
“MaxCyte’s third quarter results reflect the progress that we have made throughout 2026, with approximately 15% year-over-year core revenue growth expected in the second half of this year, exceeding the growth expectations we established at the beginning of 2026.”
Maher Masoud, President and CEO of MaxCyte
“Looking ahead, our SPL partners are at the forefront of cell therapy program development, with more late-stage programs than ever before, including two pivotal trials that could result in approvals as early as next year.”
Maher Masoud, President and CEO of MaxCyte
“Our enterprise pharma partnership is off to a strong start and represents an exciting opportunity to support its advancing cell therapy pipeline.”
Maher Masoud, President and CEO of MaxCyte
“Together, with building adoption in early research, we now have a broad set of solutions at every stage, from discovery through commercialization.”
Maher Masoud, President and CEO of MaxCyte
“We believe we have strong momentum heading into the end of the year and remain committed to executing on our priorities to drive durable long-term growth.”
Third Quarter and Recent Business Highlights: * Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related revenue * Raises Full Year 2026 Total Revenue Guidance to at least $34.5 million, reflecting a projected return to full-year revenue growth * In July, MaxCyte announced a strategic, multi-platform technology license partnership with Genentech * MaxCyte today announced the proposed acquisition of Akron Bio, a leading supplier of GMP-grade reagents and ancillary materials, expanding its offering across cell therapy manufacturing and nearly doubling revenue ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2026 financial results and raised its 2026 total revenue guidance.
Get started
Create a free account to read the full story.